ATE289586T1 - Oxamsäuren mit einer cyanogruppe als liganden für den thyroidrezeptor - Google Patents

Oxamsäuren mit einer cyanogruppe als liganden für den thyroidrezeptor

Info

Publication number
ATE289586T1
ATE289586T1 AT00301104T AT00301104T ATE289586T1 AT E289586 T1 ATE289586 T1 AT E289586T1 AT 00301104 T AT00301104 T AT 00301104T AT 00301104 T AT00301104 T AT 00301104T AT E289586 T1 ATE289586 T1 AT E289586T1
Authority
AT
Austria
Prior art keywords
prodrugs
ligands
cyano group
isomers
compounds
Prior art date
Application number
AT00301104T
Other languages
English (en)
Inventor
Robert Lee Dow
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE289586T1 publication Critical patent/ATE289586T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
AT00301104T 1999-03-01 2000-02-14 Oxamsäuren mit einer cyanogruppe als liganden für den thyroidrezeptor ATE289586T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12211999P 1999-03-01 1999-03-01

Publications (1)

Publication Number Publication Date
ATE289586T1 true ATE289586T1 (de) 2005-03-15

Family

ID=22400746

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00301104T ATE289586T1 (de) 1999-03-01 2000-02-14 Oxamsäuren mit einer cyanogruppe als liganden für den thyroidrezeptor

Country Status (10)

Country Link
US (1) US6194454B1 (de)
EP (1) EP1033364B1 (de)
JP (1) JP3564680B2 (de)
AT (1) ATE289586T1 (de)
BR (1) BR0000968A (de)
CA (1) CA2299760C (de)
DE (1) DE60018225T2 (de)
DK (1) DK1033364T3 (de)
ES (1) ES2234523T3 (de)
PT (1) PT1033364E (de)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6599942B1 (en) 1999-03-29 2003-07-29 Novartis Ag Thyromimetic organic compounds
US6790978B2 (en) 1999-03-29 2004-09-14 Novartis Ag Thyromimetic organic compounds
EP1189611B1 (de) * 1999-06-14 2006-05-03 Cancer Research Technology Limited Krebstherapie
ATE295348T1 (de) 2000-02-17 2005-05-15 Bristol Myers Squibb Co Thyroid-rezeptorliganden, die von anilin ableitbar sind
CA2403806A1 (en) * 2000-03-23 2002-09-20 Bayer Aktiengesellschaft Indoles for treating diseases that can be treated using thyroid hormones
US6664291B2 (en) 2000-03-31 2003-12-16 Pfizer, Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands
US6395784B1 (en) 2000-06-07 2002-05-28 Bristol-Myers Squibb Company Benzamide ligands for the thyroid receptor
WO2002009700A1 (en) * 2000-07-28 2002-02-07 Cancer Research Technology Limited Cancer treatment by combination therapy
RU2291707C2 (ru) * 2000-12-12 2007-01-20 Канека Корпорейшн Композиции для профилактики или облегчения синдромов множественных факторов риска
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
JP2004525109A (ja) 2001-02-15 2004-08-19 キング・ファーマシューティカルズ・インコーポレイティッド 安定化された甲状腺ホルモン医薬組成物、及びその製法
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
GB0121285D0 (en) * 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
DE60208132T2 (de) 2001-09-26 2006-07-20 Pfizer Products Inc., Groton Indolcaroboxylsäure als Thyroidrezeptor-Liganden
US6806381B2 (en) * 2001-11-02 2004-10-19 Bristol-Myers Squibb Company Process for the preparation of aniline-derived thyroid receptor ligands
US20030235609A1 (en) * 2002-01-25 2003-12-25 Lautt Wilfred Wayne Use of cholinesterase antagonists to treat insulin resistance
EP1471049A4 (de) 2002-01-30 2006-08-16 Kissei Pharmaceutical Neuer ligand für den thyroidhormonrezeptor, diesen enthaltende medizinische zusammensetzungen und deren verwendung
GB2386836B (en) * 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
CN100411618C (zh) * 2002-05-17 2008-08-20 迪欧加药品公司 有效的选择性阿片受体调制剂化合物的用途
ATE395936T1 (de) * 2002-06-20 2008-06-15 Univ Alberta Dichloracetat in kombination mit kardioprotektiven oder hämodynamischen medikamenten
AU2003267728A1 (en) * 2002-10-18 2004-05-04 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
GB2394658A (en) * 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
AU2003288034A1 (en) * 2002-11-12 2004-06-03 Novartis Ag Treatment of mesothelioma
JP4776537B2 (ja) * 2003-05-27 2011-09-21 ロベルト・ペール・ヘーガークヴィスト 糖尿病処置のためのチロシンキナーゼ阻害剤の使用
GB0321999D0 (en) * 2003-09-19 2003-10-22 Cancer Rec Tech Ltd Anti-cancer combinations
EP1689383B1 (de) * 2003-11-19 2012-10-31 Metabasis Therapeutics, Inc. Neue phosphor enthaltende thyromimetika
US20060141487A1 (en) * 2004-01-26 2006-06-29 Applera Corporation Methods, compositions, and kits for amplifying and sequencing polynucleotides
NZ549721A (en) 2004-03-05 2010-08-27 Univ Pennsylvania Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
US20050215529A1 (en) * 2004-03-24 2005-09-29 The Regents Of The University Of Michigan Method of treating oxidative stress-associated conditions with isopentenyl diphosphate
CN101891680B (zh) 2004-06-24 2014-10-29 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的调控剂
AU2005259864A1 (en) * 2004-06-30 2006-01-12 Combinatorx, Incorporated Methods and reagents for the treatment of metabolic disorders
US20080260763A1 (en) * 2004-07-01 2008-10-23 The Regents Of The University Of California High Throughput Proteomics
CN101107012A (zh) * 2004-11-24 2008-01-16 希尔氏宠物营养品公司 改进动物异生素物质肝清除率的方法
US20090176864A1 (en) * 2004-11-24 2009-07-09 Hill's Pet Nutrition, Inc. Methods For Improving Hepatic and Immune Function In An Animal
US8252742B2 (en) 2004-12-30 2012-08-28 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
CA2784197C (en) * 2004-12-30 2015-09-01 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
US20130082232A1 (en) 2011-09-30 2013-04-04 Unity Semiconductor Corporation Multi Layered Conductive Metal Oxide Structures And Methods For Facilitating Enhanced Performance Characteristics Of Two Terminal Memory Cells
US20090028925A1 (en) * 2005-05-26 2009-01-29 Erion Mark D Novel Phosphinic Acid-Containing Thyromimetics
CA2606499C (en) 2005-05-26 2017-06-13 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
US7536767B2 (en) * 2005-05-27 2009-05-26 Prairie Packaging, Inc. Method of manufacturing a reinforced plastic foam cup
US7818866B2 (en) * 2005-05-27 2010-10-26 Prairie Packaging, Inc. Method of reinforcing a plastic foam cup
US7552841B2 (en) * 2005-05-27 2009-06-30 Prairie Packaging, Inc. Reinforced plastic foam cup, method of and apparatus for manufacturing same
US7694843B2 (en) * 2005-05-27 2010-04-13 Prairie Packaging, Inc. Reinforced plastic foam cup, method of and apparatus for manufacturing same
US7814647B2 (en) * 2005-05-27 2010-10-19 Prairie Packaging, Inc. Reinforced plastic foam cup, method of and apparatus for manufacturing same
US7704347B2 (en) * 2005-05-27 2010-04-27 Prairie Packaging, Inc. Reinforced plastic foam cup, method of and apparatus for manufacturing same
CN101287460B (zh) * 2005-08-17 2012-04-25 希尔氏宠物营养品公司 预防和治疗肾病的组合物
CA2620436A1 (en) * 2005-08-26 2007-03-01 Antisoma Plc Combinations comprising dmxaa for the treatment of cancer
DK3219705T3 (da) 2005-12-28 2020-04-14 Vertex Pharma Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
US20080161279A1 (en) * 2006-12-21 2008-07-03 Wisler Gerald L Methods of Treating Obesity
EP2636407A3 (de) * 2007-03-30 2013-11-06 Tioga Pharmaceuticals, Inc. Kappa-Opiat-Agonisten zur Behandlung von diarrhöeprädominantem und wechselhaftem Reizdarmsyndrom
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
CN101475984A (zh) 2008-12-15 2009-07-08 江苏命码生物科技有限公司 一种非小细胞肺癌检测标记物及其检测方法、相关生物芯片和试剂盒
KR101727762B1 (ko) 2009-03-20 2017-04-17 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법
US8642515B2 (en) * 2009-09-04 2014-02-04 University Of Louisville Research Foundation, Inc. Genetic determinants of prostate cancer risk
EP2518158B1 (de) * 2009-12-24 2016-09-14 Micromedmark Biotech Co., Ltd Marker für pankreaskarzinom und nachweisverfahren
US20130090258A1 (en) * 2010-06-16 2013-04-11 National University Corporation Hamamatsu University School Of Medicines Method for detecting colorectal tumor
WO2012006088A1 (en) * 2010-06-29 2012-01-12 University Of Medicine And Dentistry Of New Jersey Method and kit for classifying a patient
WO2012158603A2 (en) 2011-05-13 2012-11-22 Bioo Scientific Corporation Pooled adapter strategy for reducing bias in small rna characterization
US8778843B1 (en) * 2011-08-03 2014-07-15 Fry Laboratories, L.L.C. Semi-pan-protozoal by quantitative PCR
WO2013022821A1 (en) * 2011-08-05 2013-02-14 Gen-Probe Incorporated Antiandrogen therapy monitoring methods and compositions
US20130035257A1 (en) * 2011-08-05 2013-02-07 University Of British Columbia Microfluidic arrays and methods for their preparation and use
EP2761300A4 (de) * 2011-09-27 2015-12-02 Univ Michigan Rezidivierende genfusionen bei brustkrebs
US9970060B2 (en) * 2011-11-23 2018-05-15 Medical Diagnostic Laboratories, Llc Quantitation and profiling of vaginal microflora
JP6301263B2 (ja) * 2011-12-23 2018-03-28 デピュイ・シンセス・プロダクツ・インコーポレイテッド ヒト臍帯組織由来細胞の検出
JP2015511583A (ja) 2012-02-27 2015-04-20 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 薬学的組成物およびその投与
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
US20140221424A1 (en) * 2013-01-30 2014-08-07 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for use in the treatment of cystic fibrosis
US8987327B1 (en) 2013-10-11 2015-03-24 Eugene Lipov Kits and methods for treating post traumatic stress disorder (PTSD) and hot flashes
CN107250113B (zh) 2014-10-07 2019-03-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调节蛋白的调节剂的共晶
WO2016196229A1 (en) 2015-06-01 2016-12-08 Cellular Research, Inc. Methods for rna quantification
EP3452614B1 (de) * 2016-05-02 2023-06-28 Becton, Dickinson and Company Genaue molekulare barcodierung
CA3044059A1 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
EA201992703A1 (ru) 2017-06-05 2020-04-15 Вайкинг Терапьютикс, Инк. Композиции для лечения фиброза
WO2019126209A1 (en) 2017-12-19 2019-06-27 Cellular Research, Inc. Particles associated with oligonucleotides
CA3094167A1 (en) 2018-03-22 2019-09-26 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
WO2020150356A1 (en) 2019-01-16 2020-07-23 Becton, Dickinson And Company Polymerase chain reaction normalization through primer titration
EP4188372A1 (de) 2020-07-29 2023-06-07 Amryt Pharmaceuticals Inc. Lomitapid zur verwendung in verfahren zur behandlung von hyperlipidämie und hypercholesterinämie bei pädiatrischen patienten
US12383566B2 (en) * 2021-10-29 2025-08-12 Northwestern University Inhibition of SLC transporter activity or expression to attenuate anthracycline-induced cardiotoxicity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069343A (en) 1973-03-23 1978-01-17 American Home Products Corporation Oxamic acid derivatives for the prevention of immediate type hypersensitivity reactions
US4554290A (en) 1983-06-17 1985-11-19 Ciba-Geigy Corporation Oxamic acid derivatives
GB8501372D0 (en) 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds
US5061798A (en) 1985-01-18 1991-10-29 Smith Kline & French Laboratories, Ltd. Benzyl pyridyl and pyridazinyl compounds
US5232947A (en) 1988-07-04 1993-08-03 Meiji Seika Kaisha, Ltd. Oxamic acid compounds and pharmaceutical composition for use in improvement of damaged cerebral functions of brain
US5284971A (en) 1992-07-16 1994-02-08 Syntex (U.S.A.) Inc. 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents
EP0580550B1 (de) 1992-07-21 1997-10-22 Novartis AG Oxamidsäure-Derivate als hypocholesterämische Mittel

Also Published As

Publication number Publication date
ES2234523T3 (es) 2005-07-01
DE60018225D1 (de) 2005-03-31
BR0000968A (pt) 2000-09-19
PT1033364E (pt) 2005-07-29
US6194454B1 (en) 2001-02-27
CA2299760A1 (en) 2000-09-01
EP1033364B1 (de) 2005-02-23
DE60018225T2 (de) 2005-12-29
JP3564680B2 (ja) 2004-09-15
CA2299760C (en) 2006-01-10
EP1033364A1 (de) 2000-09-06
DK1033364T3 (da) 2005-06-06
JP2000256299A (ja) 2000-09-19

Similar Documents

Publication Publication Date Title
DE60018225D1 (de) Oxamsäuren mit einer Cyanogruppe als Liganden für den Thyroidrezeptor
DK1088819T3 (da) 6-azauracilderivater som thyroidreceptorligander
AP2001002259A0 (en) Oxamic acids and derivatives as thyroid receptor ligands.
BR0101527A (pt) Ligandos de receptores de tiróide
CA2332066A1 (en) Tetrazole compounds as thyroid receptor ligands
PT882707E (pt) Novos compostos trciclicos e composicoes medicamentosas contendo os mesmos
EA200200921A1 (ru) Полуамиды малоновой кислоты и их производные в качестве лигандов тиреоидных рецепторов
DE60208132D1 (de) Indolcaroboxylsäure als Thyroidrezeptor-Liganden
ATE330930T1 (de) Neue ethylaminderivate
NO20002589D0 (no) Bifenylamidinderivater
DK0902018T3 (da) 2-(arylpheny)amino-imidazolinderivater
NO178397C (no) Substituerte 1,2,3,4-tetrahydrocyklopent[bÅindoler, 1,2,3,3a,4,8a-heksahydrocyklopent[bÅindoler og beslektede forbindelser, mellomprodukter og deres bruk som medikamenter
ATE245141T1 (de) Benzolsulfonamidderivate
ES533657A0 (es) Un procedimiento para la preparacion de nuevos derivados de pirrolo-(2,1-a)isoquilonina.
ES2085540T3 (es) 2-(3-fenilpropil)hidrazinas, productos intermedios en y un procedimiento para la preparacion de las mismas, y su uso como medicamentos.
BR0007593A (pt) Processo para preparar uma aza-macrolida com 4"(r)-nh2"

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1033364

Country of ref document: EP

REN Ceased due to non-payment of the annual fee